MY106722A - Sustained release formulations of water soluble peptides. - Google Patents

Sustained release formulations of water soluble peptides.

Info

Publication number
MY106722A
MY106722A MYPI90001133A MYPI19901133A MY106722A MY 106722 A MY106722 A MY 106722A MY PI90001133 A MYPI90001133 A MY PI90001133A MY PI19901133 A MYPI19901133 A MY PI19901133A MY 106722 A MY106722 A MY 106722A
Authority
MY
Malaysia
Prior art keywords
sustained release
water soluble
release formulations
soluble peptides
formulation
Prior art date
Application number
MYPI90001133A
Other languages
English (en)
Inventor
Wing Fong Jones
Nagele Oskar
Valliant Maulding Hawkins
Thomas Kissel Dr
Edna Pearson Jane
David Bodmer Dr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY106722A publication Critical patent/MY106722A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI90001133A 1989-07-07 1990-07-06 Sustained release formulations of water soluble peptides. MY106722A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (1)

Publication Number Publication Date
MY106722A true MY106722A (en) 1995-07-31

Family

ID=27007654

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001133A MY106722A (en) 1989-07-07 1990-07-06 Sustained release formulations of water soluble peptides.

Country Status (27)

Country Link
JP (5) JPH0832624B2 (xx)
KR (2) KR100303681B1 (xx)
AT (1) AT406225B (xx)
AU (2) AU641407B2 (xx)
BE (1) BE1004486A3 (xx)
CA (1) CA2020477C (xx)
CH (1) CH685230A5 (xx)
CY (1) CY1965A (xx)
DE (2) DE4042752B4 (xx)
DK (1) DK175849B1 (xx)
FI (3) FI108611B (xx)
FR (1) FR2649319A1 (xx)
GB (2) GB2234896B (xx)
GR (1) GR1001121B (xx)
HK (2) HK97695A (xx)
HU (2) HU221294B1 (xx)
IE (2) IE64216B1 (xx)
IL (3) IL94983A (xx)
IT (1) IT1241460B (xx)
LU (1) LU87764A1 (xx)
MY (1) MY106722A (xx)
NL (1) NL195027C (xx)
NO (2) NO302928B1 (xx)
NZ (1) NZ234384A (xx)
PT (1) PT94628B (xx)
SE (1) SE512992C2 (xx)
SG (1) SG26416G (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
EP0862419B2 (en) 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004516262A (ja) 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
JP2008518881A (ja) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JPWO2005082405A1 (ja) * 2004-02-26 2007-10-25 独立行政法人科学技術振興機構 たんぱく性薬物の注射用徐放性微粒子製剤およびその製造法
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
CA2713339C (en) 2008-01-30 2017-01-17 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2813301A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Method for removing residual organic solvent from microparticles
WO2012044675A2 (en) * 2010-09-30 2012-04-05 Surmodics Pharmaceuticals, Inc. Emulsion method for preparing low residual solvent microparticles
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (xx) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
AU5874690A (en) 1991-01-10
GB2265311A (en) 1993-09-29
DK175849B1 (da) 2005-03-29
GR900100513A (en) 1991-12-10
NO302928B1 (no) 1998-05-11
HUT54037A (en) 1991-01-28
FR2649319B1 (xx) 1994-12-09
DE4021517B4 (de) 2009-04-09
DK162590D0 (da) 1990-07-05
CA2020477C (en) 2000-11-21
JPH07285853A (ja) 1995-10-31
IE64411B1 (en) 1995-08-09
FR2649319A1 (fr) 1991-01-11
SE9002364L (sv) 1991-01-08
PT94628A (pt) 1991-03-20
JPH08198771A (ja) 1996-08-06
NO903001D0 (no) 1990-07-05
GB2234896B (en) 1994-01-19
JP2001233897A (ja) 2001-08-28
AU687553B2 (en) 1998-02-26
KR100303681B1 (ko) 2002-05-16
NL195027B (nl) 2003-08-01
IT1241460B (it) 1994-01-17
IL94983A (en) 1999-08-17
CY1965A (en) 1997-07-04
SG26416G (en) 1995-09-01
JP2931773B2 (ja) 1999-08-09
HU221294B1 (en) 2002-09-28
ATA144090A (de) 1999-08-15
AT406225B (de) 2000-03-27
JPH07309897A (ja) 1995-11-28
GB9014704D0 (en) 1990-08-22
JPH0368511A (ja) 1991-03-25
NL195027C (nl) 2003-12-02
NO983923D0 (no) 1998-08-26
SE512992C2 (sv) 2000-06-12
FI20000059A (fi) 2000-01-12
SE9002364D0 (sv) 1990-07-05
NO983923L (no) 1991-01-08
CA2020477A1 (en) 1991-01-08
FI109334B (fi) 2002-07-15
BE1004486A3 (fr) 1992-12-01
IL131880A (en) 2001-12-23
GB2234896A (en) 1991-02-20
KR910002430A (ko) 1991-02-25
IT9048113A1 (it) 1992-01-05
DE4042752B4 (de) 2009-05-07
NO320444B1 (no) 2005-12-05
DK162590A (da) 1991-01-08
HK97695A (en) 1995-06-23
AU2332195A (en) 1995-09-07
FI108611B (fi) 2002-02-28
NO903001L (no) 1991-01-08
IL94983A0 (en) 1991-06-10
IE902435A1 (en) 1991-02-13
JPH0832624B2 (ja) 1996-03-29
HU211602A9 (en) 1995-12-28
NL9001537A (nl) 1991-02-01
IE64216B1 (en) 1995-07-26
FI903429A0 (fi) 1990-07-06
HU903974D0 (en) 1990-11-28
CH685230A5 (de) 1995-05-15
LU87764A1 (fr) 1992-03-11
FI109543B (fi) 2002-08-30
PT94628B (pt) 1997-06-30
FI20000060A (fi) 2000-01-12
AU641407B2 (en) 1993-09-23
DE4021517A1 (de) 1991-01-17
HK197496A (en) 1996-11-08
IT9048113A0 (it) 1990-07-05
GB9306204D0 (en) 1993-05-19
GB2265311B (en) 1994-02-09
GR1001121B (el) 1993-04-28
IL131881A (en) 2001-12-23
KR100442931B1 (ko) 2004-08-02
NZ234384A (en) 1994-05-26

Similar Documents

Publication Publication Date Title
MY106722A (en) Sustained release formulations of water soluble peptides.
FI870155A0 (fi) Menetelmä ksantaanikumia sisältävän, kiinteän lääkevalmisteen valmistamiseksi
EP0332222A3 (en) Intravaginal delivery of biologically active polypeptides
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
CA2207078A1 (en) Insulin derivatives with increased zinc binding
HUP0000737A2 (hu) Hialuronsav mikrorészecskékbe foglalt hatóanyagokat tartalmazó nyújtott hatóanyagleadású készítmény
UA35569C2 (uk) Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
DE69524609D1 (de) Verzoegerte freisetzung von peptiden aus pharmazeutischen zusammensetzungen
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
HK1010685A1 (en) A method of preparing a freeze-dried formulation containing a drug
DK193887D0 (da) Fysiologisk aktivt peptid
RU94005001A (ru) Лиофилизат на основе пептида
EP0211601A3 (en) Stabilization of growth promoting hormones
CA2316052A1 (en) Sustained release formulations of water soluble peptides
WO1988003150A3 (fr) Preparations aminoacides contenant des peptides de n,n'-bis-l-aminoacide-l-cystine et destinees a l'administration orale et parenterale
FI991120A (fi) Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
WO1997019953A3 (de) Neue lh-rh-antagonisten mit verbesserter wirkung
ES2049617A1 (es) Procedimiento de preparacion de una composicion farmaceutica.
CA2036657A1 (en) Temporary minimal protection synthesis of lh-rh analogs
RU97120940A (ru) Пептид, обладающий иммуномодулирующей активностью, и препарат на его основе
Cerio et al. Dress code.
CS275014B2 (en) Peptides with accumulated pair of basic amino acids